文献速递神经免疫癫痫神经重症与神经感染

儿童护理个体化应用的血清神经丝轻链参考数据库:一项回顾性建模与验证研究

Serum neurofilament light chain reference database for individual application in paediatric care: a retrospective modelling and validation study.
PubMed 文献 · Lancet Neurol · 2023-07-28

本研究基于欧洲和北美两个大型队列中2667名健康儿童和青少年(0-22岁)的血清神经丝轻链(sNfL)数据,建立年龄调整的参考范围数据库,并在220名患有神经系统疾病的儿童和青少年中验证其临床效用。结果显示,健康儿童sNfL浓度在10.3岁前每年下降约6.8%,此后至22岁基本稳定;在患者群体中,年龄调整的sNfL Z评分高于健康参考人群(p<0.0001),且效应量指标(Cohen's d=1.56)高于原始sNfL浓度(d=1.28)。

要点

  • 健康儿童sNfL浓度在10.3岁前每年下降约6.8%,之后至22岁基本稳定。
  • 在神经系统疾病患儿中,年龄调整的sNfL Z评分显著高于健康儿童(p<0.0001)。
  • sNfL Z评分的效应量(Cohen's d=1.56)高于原始sNfL浓度(d=1.28)。

核心结论

  • 建立的儿童和青少年sNfL正常值可为sNfL在儿科人群中的临床应用提供基础。
  • 与绝对sNfL值相比,使用sNfL Z评分与更高的效应量指标相关,并能更准确地估计个体患者正在进行的神经轴索损伤程度。

研究设计与样本

  • 回顾性建模与验证研究,使用来自欧洲(德国巴伐利亚儿童冠状病毒抗体研究)和北美(美国儿童多发性硬化中心网络儿科病例对照队列)两个大型队列的健康儿童和青少年(0-22岁)的sNfL数据建立参考数据库。
  • 排除采样时有活动性或既往COVID-19感染或SARS-CoV-2抗体阳性,或有原发性系统性或神经系统疾病史的儿童。
  • 采用线性模型回顾性研究年龄和体重对sNfL浓度的影响,并使用广义加性模型(GAMLSS)对sNfL浓度分布随年龄相关生理变化建模,得出参考百分位和Z评分。
  • 在来自加利福尼亚大学旧金山分校儿科神经免疫门诊和雷根斯堡大学儿童医院的患有神经系统疾病(癫痫、创伤性脑损伤、细菌性中枢神经系统感染、儿童期起病多发性硬化、髓鞘少突胶质细胞糖蛋白抗体相关疾病)的儿童和青少年(1-19岁)中评估新参考数据集的临床效用。

主要发现

  • 使用2667名健康儿童和青少年(1336名女孩[50.1%]和1331名男孩[49.9%];中位年龄8.0岁[IQR 4.0-12.0])的样本生成参考数据库,覆盖新生儿期至青春期(目标年龄范围0-20岁)。
  • 在健康人群中,sNfL浓度随年龄下降,至10.3岁前估计每年下降6.8%(估计每增加1岁的乘性效应0.93 [95% CI 0.93-0.94],p<0.0001),此后至22岁基本稳定(1.00 [0.52-1.94],p>0.99)。
  • 独立于年龄,体重对sNfL浓度的影响幅度很小。
  • 使用220名患有神经系统疾病的儿童(134名女孩[60.9%]和86名男孩[39.1%];中位年龄14.7岁[IQR 10.8-16.5])的样本验证参考Z评分的临床效用。
  • 在该患者群体中,年龄调整的sNfL Z评分高于健康儿童和青少年参考人群(p<0.0001),效应量指标(Cohen's d=1.56)高于应用原始sNfL浓度(d=1.28)。

临床怎么用

  • 作者认为,建立的儿童和青少年sNfL正常值可为sNfL在儿科人群中的临床应用提供基础。
  • 作者认为,与绝对sNfL值相比,使用sNfL Z评分与更高的效应量指标相关,并能更准确地估计个体患者正在进行的神经轴索损伤程度。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Neurological conditions represent an important driver of paediatric disability burden worldwide. Measurement of serum neurofilament light chain (sNfL) concentrations, a specific marker of neuroaxonal injury, has the potential to contribute to the management of children with such conditions. In this context, the European Medicines Agency recently declared age-adjusted reference values for sNfL a top research priority. We aimed to establish an age-adjusted sNfL reference range database in a population of healthy children and adolescents, and to validate this database in paediatric patients with neurological conditions to affirm its clinical applicability. METHODS: To generate a paediatric sNfL reference dataset, sNfL values were measured in a population of healthy children and adolescents (aged 0-22 years) from two large cohorts in Europe (the Coronavirus Antibodies in Kids from Bavaria study, Germany) and North America (a US Network of Paediatric Multiple Sclerosis Centers paediatric case-control cohort). Children with active or previous COVID-19 infection or SARS-CoV-2 antibody positivity at the time of sampling, or a history of primary systemic or neurological conditions were excluded. Linear models were used to restrospectively study the effect of age and weight on sNfL concentrations. We modelled the distribution of sNfL concentrations as a function of age-related physiological changes to derive reference percentile and Z score values via a generalised additive model for location, scale, and shape. The clinical utility of the new reference dataset was assessed in children and adolescents (aged 1-19 years) with neurological diseases (epilepsy, traumatic brain injury, bacterial CNS infections, paediatric-onset multiple sclerosis, and myelin oligodendrocyte glycoprotein antibody-associated disease) from the paediatric neuroimmunology clinic at the University of California San Francisco (San Francisco, CA, USA) and the Children's Hospital of the University of Regensburg (Regensburg, Germany). FINDINGS: Samples from 2667 healthy children and adolescents (1336 [50·1%] girls and 1331 [49·9%] boys; median age 8·0 years [IQR 4·0-12·0]) were used to generate the reference database covering neonatal age to adolescence (target age range 0-20 years). In the healthy population, sNfL concentrations decreased with age by an estimated 6·8% per year until age 10·3 years (estimated multiplicative effect per 1 year increase 0·93 [95% CI 0·93-0·94], p<0·0001) and was mostly stable thereafter up to age 22 years (1·00 [0·52-1·94], p>0·99). Independent of age, the magnitude of the effect of weight on sNfL concentrations was marginal. Samples from 220 children with neurological conditions (134 [60·9%] girls and 86 [39·1%] boys; median age 14·7 years [IQR 10·8-16·5]) were used to validate the clinical utility of the reference Z scores. In this population, age-adjusted sNfL Z scores were higher than in the reference population of healthy children and adolescents (p<0·0001) with higher effect size metrics (Cohen's d=1·56) compared with the application of raw sNfL concentrations (d=1·28). INTERPRETATION: The established normative sNfL values in children and adolescents provide a foundation for the clinical application of sNfL in the paediatric population. Compared with absolute sNfL values, the use of sNfL Z score was associated with higher effect size metrics and allowed for more accurate estimation of the extent of ongoing neuroaxonal damage in individual patients. FUNDING: Swiss National Science Foundation, US National Institutes of Health, and the National Multiple Sclerosis Society.

来源:Lancet Neurol,查看原文。版权归原作者所有。

引用

  1. Abdelhak A, Petermeier F, Benkert P, et al. Serum neurofilament light chain reference database for individual application in paediatric care: a retrospective modelling and validation study. Lancet Neurol. 2023. PMID: 37524100. doi:10.1016/S1474-4422(23)00210-7

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。